Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Oncopeptides in connection with a directed share issue (5)
Mandate

Vinge advises Oncopeptides in connection with a directed share issue

July 15, 2022 Banking and Finance Capital Markets and Public M&A

The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncopeptides will raise proceeds of approximately SEK 435,6 million, before issue costs. The price per share in the share issue corresponds to the closing price on Nasdaq Stockholm the day of the share issue.

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors.

Oncopeptides is a biotech company focused on research and development of pharmaceuticals for difficult-to-treat haematological diseases. The Company uses its proprietary PDC platform to develop peptide-drug conjugated compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. The company’s shares are admitted to trading on Nasdaq Stockholm.

Vinge’s team has consisted of Dain Hård Nevonen, Linnéa Sellström (capital markets), and Louise Brorsson Salomon, Arvid Weimers and Kamyar Najmi (financing).

Related

Vinge advises Morrow Bank AB (publ) in connection with the bank’s sale of parts of MedMera Bank and the sale of NPL portfolios

 Vinge has advised Morrow Bank AB (publ) in connection with the divestment of parts of MedMera Bank’s operations to a leading global credit investment firm. The divestment is structured as a sale of shares and priced at a premium of approximately SEK 90 million above equity value as per the completion date. The transaction includes parts of MedMera’s banking operations such as IT infrastructure, organisation and management, whilst Morrow Bank retains MedMera’s performing loans, deposits, customers, the MedMera brand, the Coop partnership agreement as well as key personnel.
September 15, 2026

Vinge advises HealthCap in conjunction with its investment in AMRA Medical

 HealthCap is investing in AMRA Medical AB, a company that analyses whole-body MRI images to classify and quantify an individual’s muscle and fat tissue throughout the body and places this in relation to human health and disease.
September 15, 2026

Vinge has advised EQT managed Scaleup Europe Fund on its investment in Tandem Health

 Vinge has advised EQT managed Scaleup Europe Fund as lead investor in Tandem Health's USD 100 million Series B investment round, with participation from existing investors Kinnevik, Northzone, Amino Collective and Visionaries. Tandem Health is an AI healthcare company founded in 2023 and headquartered in Sweden. Tandem Health operates as an AI partner within the healthcare sector across Europe, providing AI medical assistant support to clinicians in connection with patient visits.
September 15, 2026